Oritavancin
Who holds supplier records for Oritavancin? No organisation holds a current US Type II DMF or EU CEP for Oritavancin in the registers PharmaTek covers.
Most records are filed under another form of this substance: Oritavancin Diphosphate (1 current source). A DMF or CEP is listed under the form it names.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Oritavancin: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/oritavancin
Reading the evidence
- No current DMF or CEP on record
The covered registers hold no supplier record for this substance. This is not evidence that no one makes it: suppliers may file under another name, sell outside the US and EU, or use an ASMF.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Oritavancin expires 16 Jul 2035. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (0)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Oritavancin. Country is the organisation's recorded country, not necessarily the manufacturing site.
Not found in the covered registers (FDA DMF list, EDQM). This is not evidence that no supplier exists.
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (2 listed products contain Oritavancin). The latest listed patent expires 16 Jul 2035. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Other forms of this substance
A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:
Overview
Oritavancin is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL1688530).
Chemical identity
- IUPAC name
- (1S,2R,18R,19R,22S,25R,28R,40S)-2-[(2R,4S,5R,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-22-(2-amino-2-oxoethyl)-5,15-dichloro-48-[(2S,3R,4S,5S,6R)-3-[(2S,4S,5R,6S)-4-[[4-(4-chlorophenyl)phenyl]methylamino]-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-18,32,35,37-tetrahydroxy-19-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8,10,12(48),14,16,29(45),30,32,34(39),35,37,46,49-pentadecaene-40-carboxylic acid
- Canonical SMILES
- C[C@H]1[C@@H]([C@@](C[C@@H](O1)O[C@H]2[C@H]3C(=O)N[C@@H](C4=C(C(=CC(=C4)O)O)C5=C(C=CC(=C5)[C@H](C(=O)N3)NC(=O)[C@H]6C7=CC(=C(C(=C7)OC8=C(C=C2C=C8)Cl)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O[C@H]1C[C@]([C@H]([C@@H](O1)C)O)(C)NCC1=CC=C(C=C1)C1=CC=C(C=C1)Cl)OC1=C(C=C(C=C1)[C@H]([C@H](C(=O)N[C@H](C(=O)N6)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)O)C(=O)O)(C)N)O
- InChIKey
- VHFGEBVPHAGQPI-LXKZPTCJSA-N
- Synonyms
- LY-333328, LY333328, Oritavancin, Oritavancina, Oritavancine, Chlorobiphenyl-chloroeremomycin, CHEBI:82699, oritavancinum, oritavacin diphosphate, RefChem:57173, J01XA05, Oritavancin [INN]
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Lipoglycopeptide Antibacterial
- Mechanism of action
- Cytochrome P450 2C19 Inhibitors; Cytochrome P450 2C9 Inhibitors; Cytochrome P450 2D6 Inducers; Cytochrome P450 3A4 Inducers
- Chemical structure
- Lipoglycopeptides
Record history
PharmaTek records which organisations hold a current DMF or CEP for Oritavancin every week, starting 23 Oct 2026. Additions and lapses will appear here from the next weekly release.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Does the FDA Orange Book list patents for products containing Oritavancin?
Yes. The latest patent listed for an approved US product containing Oritavancin expires 16 Jul 2035, across 2 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Oritavancin supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Oritavancin?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.